Substrate
science

SpaceX Files for IPO Targeting Up to $75 Billion Raise

SpaceX submitted its S-1 filing on Wednesday to list shares on Nasdaq under ticker SPCX. The company reported $18.7 billion in 2025 revenue and a $2.6 billion operating loss.

Bloomberg
FO
Benzinga
CBS News
Forbes
Los Angeles Times
6 sources·May 20, 9:39 PM(8 days ago)·1m read
|
SpaceX Files for IPO Targeting Up to $75 Billion RaiseBenzinga
Audio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.

SpaceX filed its S-1 registration statement with the Securities and Exchange Commission on Wednesday evening, advancing plans for what analysts expect could become the largest initial public offering in history. The filing disclosed that the company plans to list its shares on the Nasdaq and Nasdaq Texas exchanges under the ticker SPCX. 75 trillion.

6 billion operating loss, according to the filing. 4 percent increase from the same period in 2025. 27 billion in the first quarter of 2026, compared with a $528 million loss in the first quarter of 2025.

The prospectus also provided details on SpaceX’s ownership of xAI and Starlink, as well as its plans to pursue asteroid mining operations. Elon Musk holds more than 50 percent of the voting power and will retain control over board selection after the offering.

Mr. As a result, Mr. 5 trillion for AI services.

SpaceX filed a confidential IPO registration with the SEC last month. Reuters reported that the company could begin its roadshow on June 4, price the offering as early as June 11, and begin trading as soon as June 12. The filing marks the first public disclosure of detailed financial information for the company founded in 2002.

Key Facts

$75 billion
target raise at $1.75 trillion valuation
$18.7 billion
2025 revenue with $2.6 billion operating loss
SPCX
planned Nasdaq ticker for SpaceX shares
More than 50%
voting control retained by Elon Musk

Story Timeline

6 events
  1. May 20, 8:03 PM ET

    2 new sources added: Forbes, Los Angeles Times

    2 sourcesForbes · Los Angeles Times
  2. Last month

    SpaceX filed a confidential IPO registration with the SEC.

    2 sourcesCBS News · FortuneMagazine
  3. Wednesday evening

    SpaceX submitted its public S-1 filing to the SEC.

    4 sourcesBenzinga · FortuneMagazine · CBS News · business
  4. June 4, 2026

    SpaceX is expected to begin its IPO roadshow.

    1 sourceBenzinga
  5. June 11, 2026

    SpaceX could price its IPO shares.

    1 sourceBenzinga
  6. June 12, 2026

    SpaceX shares could begin trading on Nasdaq under ticker SPCX.

    1 sourceBenzinga

Potential Impact

  1. 01

    Musk will retain majority voting control after the offering.

  2. 02

    SpaceX will gain access to public capital markets for expansion.

  3. 03

    Investors will receive first detailed financial disclosures on Starlink and xAI.

Transparency Panel

Sources cross-referenced6
Confidence score86%
Synthesized bySubstrate AI
Word count214 words
PublishedMay 20, 2026, 9:39 PM
Bias signals removed2 across 2 outlets
Signal Breakdown
Editorializing 1Amplifying 1

Related Stories

WHO Director Visits Congo as Ebola Outbreak SpreadsNpr
science3 hrs ago

WHO Director Visits Congo as Ebola Outbreak Spreads

The head of the World Health Organization arrived in Kinshasa to support efforts against a rare Ebola strain. Health workers face equipment shortages, community distrust, and armed conflict in affected provinces.

Npr
France 24
2 sources
Benzinga Publishes Article on Biotech Stocks During Pandemic Recoveryfinance.yahoo.com
science5 hrs agoDeveloping

Benzinga Publishes Article on Biotech Stocks During Pandemic Recovery

Benzinga published an article titled 'Best Biotech Stocks Right Now' that addresses the sector's position during global recovery from the pandemic. The piece notes government institutions and professional traders are focusing on biotech companies for vaccine and booster developme…

Benzinga
1 source
FDA Panel Recommends XFG Variant for Fall Covid Shotsmedpagetoday.com
science1 hr agoDeveloping

FDA Panel Recommends XFG Variant for Fall Covid Shots

Replimune will submit an application to the FDA for the third time. Pfizer and Innovent Biologics reached a collaboration agreement valued at up to $10.5 billion.

Stat
1 source